Physician profile
Michelle Sit
NPI 1740269513
$2,656.99
in general payments reported to CMS, 2019-2025
15 companies · $1,458 in 2025
The $1,458 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $27.14 · 2022: $116 · 2024: $735 · 2025: $1,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,193.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $716.44 | 2024-2025 | Krystexxa, Otezla, Tavneos |
| Abbvie INC. | $564.39 | 2024-2025 | |
| Ucb, INC. | $441.84 | 2024-2025 | Bimzelx |
| Genentech USA, INC. | $255.58 | 2019-2025 | Gazyva |
| Janssen Biotech, INC. | $152.23 | 2024-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $149.24 | 2025 | |
| Gilead Sciences, INC. | $102.27 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.37 | 2019 | |
| Aurinia Pharma U.S., INC. | $47.08 | 2022 | |
| Abbott Laboratories | $46.36 | 2019-2022 | |
| Biogen, INC. | $25.65 | 2022 | |
| Glaxosmithkline, LLC. | $25.00 | 2025 | Benlysta |
| Astrazeneca Pharmaceuticals Lp | $22.31 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.96 | 2025 | Iclusig |
| Janssen Pharmaceuticals, INC | $12.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Sit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.